Coverage at a glance
| Indication | Coverage |
|---|---|
| Obesity / weight management (KP Northwest, Oregon and Washington) | Covered with PA |
| Obstructive sleep apnea (SURMOUNT-OSA, KP Northwest) | Covered with PA |
| Obesity / weight management (KP California) | Not covered |
| Obesity / weight management (KP Mid-Atlantic, Virginia, Maryland, DC) | Covered with PA |
Plan type: HMO commercial and Medicare Advantage, all regions. Each indication below lists the BMI and clinical thresholds, the prior-authorization documentation, and the published policy it comes from.
This varies by plan. KP commercial employer group plans can include or exclude anti-obesity drug coverage as a benefit design choice, the same as other major insurers. Even within a region, a self-funded employer plan may exclude weight-loss drugs while a fully-insured KP plan in the same region covers them. Confirm coverage through your member portal at kp.org or call the member services number on your card before starting therapy.
One BCBS company, not all. Kaiser Permanente operates as separate licensed health plans by region: Northern California, Southern California, Northwest (OR/WA), Mid-Atlantic (VA/MD/DC), Colorado, Georgia, Hawaii, and Washington. Each region sets its own formulary. This page summarizes what published documents show for the most searchable regions; it is not a complete national policy.
Coverage by indication
| BMI threshold | BMI 30 or higher, or BMI 27 or higher with hypertension, type 2 diabetes, or hyperlipidemia |
| Step therapy | Wegovy: must have failed 3-month trials of phentermine, diethylpropion, Qsymia, AND Contrave, plus a 3-month trial of Ozempic (semaglutide 1 mg or 2 mg). Zepbound: must have failed trials of at least two agents (phentermine, diethylpropion, Qsymia, or Contrave) AND a semaglutide trial, or have a documented contraindication or allergy to semaglutide. |
What the prior authorization needs:
- Age 18 or older
- BMI within the accepted threshold
- KP NW prescription from a KP-affiliated provider
- Step therapy requirements met or documented contraindication
- Active participation in a diet and exercise program
Source: Kaiser Permanente Northwest, Wegovy Formulary Coverage Document (healthy.kaiserpermanente.org). Official payer formulary PDF (public URL confirmed, binary; criteria cross-checked against the corresponding KP NW Zepbound formulary document and independent formulary analysis by SingleCare citing the same KP NW PDFs). Verified June 18, 2026. This row is marked lower confidence: the policy document was confirmed at its public URL but served as an unreadable file, so the policy number and framework were cross-checked against secondary sources.
| BMI threshold | BMI 30 or higher |
| Sleep study (AHI) | Moderate to severe OSA confirmed by sleep study within the past 3 years |
What the prior authorization needs:
- Age 18 or older
- OSA confirmed by polysomnography or home sleep apnea test within the past 3 years
- BMI 30 or higher
- KP NW prescription
- Separate PA criteria from the weight-management indication
Source: Kaiser Permanente Northwest, Zepbound Formulary Coverage Document (healthy.kaiserpermanente.org). Official payer formulary PDF (public URL confirmed, binary; OSA indication criteria cross-checked against independent formulary analysis citing this document). Verified June 18, 2026. This row is marked lower confidence: the policy document was confirmed at its public URL but served as an unreadable file, so the policy number and framework were cross-checked against secondary sources.
KP California's commercial and ACA Marketplace formulary, updated June 1, 2026, severely restricts Wegovy and Zepbound for obesity on standard commercial plans. Coverage was removed for weight management when BMI is below 40 effective January 1, 2025, which effectively excludes the majority of patients who present at BMI 30 to 39. The practical impact is that most KP California commercial members do not have covered access to Wegovy or Zepbound for obesity. KP Medi-Cal (the California Medicaid plan) separately removed weight-management GLP-1s effective January 1, 2026.
| Effective date | 2025-01-01 |
Source: Kaiser Permanente California, 2026 Commercial and Marketplace Drug Formulary (updated June 1, 2026). Official payer formulary PDF (public URL confirmed, binary; restriction framing confirmed via reporting on the January 2025 KP CA coverage change). Verified June 18, 2026. This row is marked lower confidence: the policy document was confirmed at its public URL but served as an unreadable file, so the policy number and framework were cross-checked against secondary sources.
KP Mid-Atlantic publishes separate prior authorization forms for Wegovy/Saxenda (HMO Exchange plan type) and Zepbound (Health Choice plan type) on the healthy.kaiserpermanente.org domain. The existence of published PA forms confirms coverage is available with authorization; the specific BMI and step-therapy criteria are in the PA form PDFs, which are not text-readable. Contact KP Mid-Atlantic member services to confirm your specific plan's criteria.
What the prior authorization needs:
- PA form required: separate forms for Wegovy/Saxenda (HMO Exchange plan type) and Zepbound (Health Choice plan type)
- Submit the plan-specific PA form through a KP Mid-Atlantic-affiliated provider
- Initial authorization and continuation authorization both require supporting documentation
Source: Kaiser Permanente Mid-Atlantic, Prior Authorization Form for Weight Management Agents (Wegovy and Saxenda), HMO Exchange 2024. Official payer PA form PDF (public URL confirmed, binary; Zepbound Health Choice PA form also confirmed at healthy.kaiserpermanente.org/content/dam/kporg/final/documents/community-providers/mas/ever/health-choice-prior-authorization-pa-form-for-zepbound-tirzepatide.pdf). Verified June 18, 2026. This row is marked lower confidence: the policy document was confirmed at its public URL but served as an unreadable file, so the policy number and framework were cross-checked against secondary sources.
Important exclusions
- KP California (Northern and Southern): commercial formulary severely restricts Wegovy and Zepbound for obesity, effectively requiring BMI 40 or higher on most commercial plans as of January 1, 2025
- KP Medicare Advantage follows the federal Part D obesity exclusion; weight-loss-only indications are not covered
- KP FEHB plans operate under the OPM mandate and may have different coverage than commercial KP plans in the same region
What to do next
If you qualify under one of the covered indications above, prior authorization is the path. Match the documentation in the requirements list then have your prescriber submit it.
- Browse the prior-authorization letter library for a template that matches your plan and indication.
- Read the full coverage picture, denial reasons, and the four appeal pathways at GLP-1 insurance coverage.
- Call the number on your insurance card and ask whether your specific plan includes the weight-management drug benefit before you submit.
- If your plan does not cover the indication you need, compare cash-pay options in the cost guide and the cheapest legitimate programs.
Frequently asked questions
Does Kaiser Permanente cover Wegovy and Zepbound?
It depends on which KP region you are in and what your plan includes. Kaiser Permanente Northwest (Oregon and Washington) covers both drugs with prior authorization and step therapy. Kaiser Permanente California's commercial formulary severely restricts obesity-indication GLP-1s. KP Mid-Atlantic publishes separate PA forms for Wegovy and Zepbound. Because KP operates as independent regional health plans, there is no single national coverage answer. This reflects the published policy verified June 2026.
What does Kaiser Permanente require to approve Wegovy and Zepbound?
For obesity / weight management (KP Northwest, Oregon and Washington): The BMI requirement is BMI 30 or higher, or BMI 27 or higher with hypertension, type 2 diabetes, or hyperlipidemia. Wegovy: must have failed 3-month trials of phentermine, diethylpropion, Qsymia, AND Contrave, plus a 3-month trial of Ozempic (semaglutide 1 mg or 2 mg). Zepbound: must have failed trials of at least two agents (phentermine, diethylpropion, Qsymia, or Contrave) AND a semaglutide trial, or have a documented contraindication or allergy to semaglutide.
Why might Kaiser Permanente deny Wegovy and Zepbound even if I meet the criteria?
KP commercial employer group plans can include or exclude anti-obesity drug coverage as a benefit design choice, the same as other major insurers. Even within a region, a self-funded employer plan may exclude weight-loss drugs while a fully-insured KP plan in the same region covers them. Confirm coverage through your member portal at kp.org or call the member services number on your card before starting therapy.
Coverage for other payers
See the full payer coverage index for every plan we have sourced.
How we built this page
Each page is built from a published payer policy document, government statute, or independent formulary analysis (KFF). Every indication row carries the source URL and the date we verified it. Where a payer's policy PDF was confirmed at its public URL but served as an unreadable binary, the policy number and coverage framework were cross-checked against secondary sources; those rows are marked lower confidence. Commercial coverage often depends on whether an employer elected the weight-management benefit. Those rows say varies by plan rather than a flat yes.
This is reference information, not medical or legal advice, and not a guarantee of coverage. GLP-1 coverage policies change often. Always confirm the current policy with your insurer using the number on your card before you rely on this page. If your experience differs from what is shown here, email hello@glpchart.com with the details and we will re-verify.
